96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients

BACKGROUND AND AIMS: Tenofovir amibufenamide (TMF) is a novel phosphoramidated prodrug of tenofovir with noninferior efficacy and better bone and renal safety to tenofovir disoproxil fumarate (TDF) in 48 weeks of treatment. Here, we update 96-week comparison results. METHODS: Patients with chronic h...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhihong, Jin, Qinglong, Zhang, Yuexin, Gong, Guozhong, Wu, Guicheng, Yao, Lvfeng, Wen, Xiaofeng, Gao, Zhiliang, Huang, Yan, Yang, Daokun, Chen, Enqiang, Mao, Qing, Lin, Shide, Shang, Jia, Gong, Huanyu, Zhong, Lihua, Yin, Huafa, Wang, Fengmei, Hu, Peng, Wu, Qiong, Pan, Chao, Jia, Wen, Li, Chuan, Sun, Chang’an, Niu, Junqi, Hou, Jinlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037506/
https://www.ncbi.nlm.nih.gov/pubmed/36969889
http://dx.doi.org/10.14218/JCTH.2022.00058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037506/
https://www.ncbi.nlm.nih.gov/pubmed/36969889
http://dx.doi.org/10.14218/JCTH.2022.00058

Ejemplares similares